Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-415-7 | CAS number: 7540-51-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Genetic toxicity in vitro:
These endpoints were fulfilled using read across from Citonellol (3,7-dimethyloct-6-en-1-ol), Nerol (cis-3,7-dimethyl-2,6-octadien-1-ol ) and Geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol). Data from tests performed with the structurally comparable compounds nerol (cis-3,7-dimethyl-2,6-octadien-1-ol) or the respective stereoisomer geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol) were used to address this endpoint via read across. Inclusion of nerol/geraniol into this assessment is justified by the structural similarity with citronellol (3,7-dimethyloct-6-en-1-ol). These structures are identical except for an additional double bond found in nerol/geraniol. The structure of nerol/geraniol is considered to represent a worst case when compared to citronellol based on this second double bond as possible additional reactive feature. A putative steric hindrance to the action of cytochromes such as those present in the S9 mix due to the additional double bond is not to be expected. Furthermore, relevant physicochemical parameters show comparability between nerol/geraniol and citronellol (molecular weight of 154.2 and 156.3 ; log Pow at 2.6 and 3.41; vapour pressure of 1 and 8.6 Pa; water solubility of 769 and 307 mg/l respectively).
Mutagenicity of citronellol in bacteria was analyzed in a study performed under GLP according to OECD guideline 471 and EU method B.13/14 (BASF, 1991). In this study bacteria strains S. typhimurium TA 1535, TA 1537, TA 98 and TA 100 were treated with citronellol at concentrations of 8 - 500 µg/plate with and without metabolic activation by S9 fraction from Aroclor induced Sprague-Dawley rats. The strains S. typhimurium TA 100 and TA 98 were also exposed to 5000 µg/plate citronellol. Although bacteriotoxic effects at doses >= 500 µg/plate were noted, no increase in revertant colonies was observed. Therefore citronellol was not mutagenic in bacteria under the chosen testing conditions.
In a study in literature, performed by the National Toxicology Program (NTP) of the US National Institute of Health according to internal guidelines, bacteria strains S. typhimurium TA 1535, TA 97, TA 98 and TA 100 were treated with concentrations of 0, 1, 3, 10, 33, 100, 333 mg/plate citronellol in DMSO with and without metabolic activation by induced male Sprague Dawley rat liver S9 mix and induced male Syrian hamster liver S9 mix (NTP, 2002). Although bacteriotoxic effects were seen in the highest dose experiments, no increase in revertant colonies was observed. Therefore citronellol was not mutagenic in bacteria under the chosen testing conditions.
In order to support the data available for citronellal, data from an AMES test performed with the structurally comparable compound nerol (cis-3,7-dimethyl-2,6-octadien-1-ol) are included into the weight of evidence.
Genetic toxicity of nerol was analyzed in a bacterial reverse mutation assay performed under GLP according to OECD guideline 471 (Symrise, 2000). Bacteria strains S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102 were treated with nerol at concentrations of 5, 15, 50, 150, 500, 1500 and 5000 µg/plate with and without metabolic activation by Aroclor-induced rat liver S9 mix. As a result, cytotoxicity was observed at 1500 ug/plate in TA100 and TA 102, and in TA98, TA1535 and TA1537 at a concentration of 5000 µg/plate. However, nerol was found to be not mutagenic under conditions of the study.
Overall in a weight of evidence and on the basis of the data available, citronellol is considered to be not mutagenic in bacteria.
In a chromosomal aberration test, concentrations of 0.0313, 0.0625, 0.125 mg/ml geraniol were tested in mammalian CHL cells 1-164 cells for clastogenic effects (Ishidate, 1984). After 48 h, 8% of the cells were polyploid (slightly, but significant elevated compared to control), and 4% of the cells showed chromosomal aberrations (not elevated compared to control). Thus, the test results were regarded as ambiguous.
In the other study, mammalian cells concentrations of 0, 33.3, 100, 333 and 1000 µM were tested in CHO cells during a sister chromatid exchange assay (Sasaki, 1989). Although cytotoxicity was noted at a concentration of 1000 µM, no substance induced chromatid exchange was detected.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Guideline study (OECD) acc. to GLP, with limitations acc. to current standart protocols
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- yes
- Remarks:
- analytical investigations (stability of the test substance in the carrier) were not carried out; only 4 strains tested
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Version / remarks:
- EEC Directive 84/449, B14
- GLP compliance:
- yes
- Remarks:
- Department of Toxicology, BASF AG
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- His operon
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 fraction from Aroclor induced Sprague-Dawley rats
- Test concentrations with justification for top dose:
- 0.8 - 5000 µg/plate - SPT: TA100, TA98;
0.8 - 500 µg/plate - SPT: TA1535, TA1537, PIT: all tester strains
SPT = standard plate test
PIT = preincubation test - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: complete solubility of the test substance in DMSO - Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- yes
- Remarks:
- sterility control
- Positive controls:
- yes
- Positive control substance:
- other: 2-aminoanthracene, 10 µg/plate in DMSO; TA 1535, TA 1537, TA 98 and TA 100
- Remarks:
- with metabolic activation
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- yes
- Remarks:
- sterility control
- Positive controls:
- yes
- Positive control substance:
- N-ethyl-N-nitro-N-nitrosoguanidine
- Remarks:
- without metabolic activation Migrated to IUCLID6: 5 µg/plate, in DMSO; TA 100 and TA 1535
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- yes
- Remarks:
- sterility control
- Positive controls:
- yes
- Positive control substance:
- other: 4-nitro-o-phenylendiamine; 10 µg, in DMSO; TA 98
- Remarks:
- without metabolic activation
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- yes
- Remarks:
- sterility control
- Positive controls:
- yes
- Positive control substance:
- 9-aminoacridine
- Remarks:
- without metabolic activation Migrated to IUCLID6: 100 µg/plate, in DMSO; TA 1537
- Details on test system and experimental conditions:
- positive control substances:
2-AA: 2-aminoanthracene
MNNG: N-methyl-N'-nitro-N-nitroso-guanidine
NPD: 4-nitro-o-phenylendiamine
AAC: 9-aminoacridine
1st experiment:
An SPT with TA 98 and TA 100 showed, that citronellol conentrations >500 µg/plate were cytotoxic.
2nd experiment:
In the second STP with all tester strains concentrations were adapted with 500 µg/plate being the highest concentration.
3rd experiment:
An PIT with all strains and the adapted concentrations was performed. Since in the second SPT colony scoring of TA 98 was not possible due to contamination, the SPT with this strain was repeated additional to the PIT. - Evaluation criteria:
- In general, a substance to be characterized as positive in the Ames test has to fulfill the following requirements:
- doubling of the spontaneous mutation rate (control)
- dose-response relationship
- reproducibility of the results - Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- other: bacteriotoxic effect at doses >= 500 µg/plate
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results:
negative - Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- other: NTP standard protocol
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Principles of method if other than guideline:
- Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res. 2000 Nov 20;455(1-2):29-60.
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- His operon
- Species / strain / cell type:
- S. typhimurium TA 97
- Species / strain / cell type:
- S. typhimurium TA 98
- Species / strain / cell type:
- S. typhimurium TA 100
- Species / strain / cell type:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Metabolic activation system:
- induced male Sprague Dawley rat liver S9 and induced male Syrian hamster liver S9
- Test concentrations with justification for top dose:
- 0, 1, 3, 10, 33, 100, 333 µg/ plate
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Untreated negative controls:
- not specified
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- other: 2-aminoanthracene; TA 97, TA 98, TA 100, TA 1535
- Remarks:
- with metabolic activation
- Untreated negative controls:
- not specified
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- 2-nitrofluorene
- Remarks:
- without metabolic activation Migrated to IUCLID6: TA 98
- Untreated negative controls:
- not specified
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- Remarks:
- without metabolic activation Migrated to IUCLID6: TA100 and TA1535
- Untreated negative controls:
- not specified
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- 9-aminoacridine
- Remarks:
- without metabolic activation Migrated to IUCLID6: TA 97
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: preincubation
DURATION
- Preincubation period: 20 minutes
- Exposure duration: usually 2 days - Evaluation criteria:
- Pattern and the strength of the mutant response are taken into account in determining the mutagenicity of a chemical. All observed responses are verified in repeat tests. If no increase in mutant colonies is seen after testing several strains under several different culture conditions, the test chemical is considered to be nonmutagenic in the Ames test.
- Species / strain:
- S. typhimurium, other: TA 97, TA 98, TA 100, TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- at 333 µg/plate
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not specified
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: observed at 333 mg/plate - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: acceptable, well documented publication
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- chromosomal abberration tests in vitro using a Chinese hamster fibroblast cell line
- GLP compliance:
- not specified
- Type of assay:
- in vitro mammalian chromosome aberration test
- Species / strain / cell type:
- other: CHL cells 1-164
- Metabolic activation:
- without
- Test concentrations with justification for top dose:
- 0.0313, 0.0625, 0.125 mg/ml
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 24 h or 48 h
- Fixation time (start of exposure up to fixation or harvest of cells): 2 h
SPINDLE INHIBITOR (cytogenetic assays): colcemid, 0.2 µg/ml
STAIN (for cytogenetic assays): Giemsa
NUMBER OF CELLS EVALUATED: 100 - Evaluation criteria:
- - The results were considered negative if the incidence of aberrations was less than 4.9%, equivocal if it was between 5.0 and 9.9%, and positive if it was more than 10.0%.
- When dose-response relationships were not found, additional experiments were carried out at similar dose levels. - Statistics:
- - For a quantitative evaluation of the clastogenic potential of positive samples, the D20 (dose in mg/ml at which structural aberrations (including gaps) were detected in 20% of metaphases observed) was determined.
- Additionally, the TR value (indicates frequency of cells with exchange-type aberrations per unit dose (mg/ml)) was calculated.
- A high TR value exists for chemicals that show carcinogenic potential in animals. - Species / strain:
- other: CHL cells 1-164
- Metabolic activation:
- without
- Genotoxicity:
- ambiguous
- Cytotoxicity / choice of top concentrations:
- not specified
- Vehicle controls validity:
- not specified
- Untreated negative controls validity:
- not specified
- Positive controls validity:
- not specified
- Conclusions:
- Interpretation of results:
ambiguous - Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: acceptable, well documented publication
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- in vitro cytogenetic assay in Chinese hamster ovary cells (CHO-K1)
- GLP compliance:
- not specified
- Type of assay:
- sister chromatid exchange assay in mammalian cells
- Species / strain / cell type:
- other: Chinese hamster CHO-K1 cells
- Metabolic activation:
- without
- Test concentrations with justification for top dose:
- 0; 33,3; 100; 333; 1000 µM
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 21 h
- Selection time (if incubation with a selection agent): 21 h
SELECTION AGENT (mutation assays): mitomycin C
SPINDLE INHIBITOR (cytogenetic assays): colchicine, 50 g/ml, 2 h
STAIN (for cytogenetic assays): Giemsa
NUMBER OF REPLICATIONS: 3
NUMBER OF CELLS EVALUATED: 50 metaphases /culture - Species / strain:
- Chinese hamster Ovary (CHO)
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- other: at 1000 µM
- Conclusions:
- Interpretation of results:
negative - Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: guideline study according to GLP
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- yes
- Remarks:
- no preincubation method performed
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- His operon
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Species / strain / cell type:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 liver homogenate from Aroclor 1254 pretreated male rats
- Test concentrations with justification for top dose:
- - Prescreen: 5 - 5000 µg/plate
- Test: 5, 15, 50, 150, 500, 1500, 5000 µg/plate - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- 2-nitrofluorene
- Remarks:
- without metabolic activation Migrated to IUCLID6: 2.5 µg/plate (TA98) in DMSO
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- Remarks:
- without metabolic activation Migrated to IUCLID6: 0.7 µg/plate (TA100, TA1535) in water
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- 9-aminoacridine
- Remarks:
- without metabolic activation Migrated to IUCLID6: 50 µg/plate (TA1537) in water
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- mitomycin C
- Remarks:
- without metabolic activation Migrated to IUCLID6: 0.15 µg/plate (TA102) in water
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- other: 2-aminoanthracene, 0.8 µg/plate (TA98, TA100, TA102, TA1535), 1.7 µg/plate (TA1537) in DMSO
- Remarks:
- with metabolic activation
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in agar (plate incorporation)
DURATION
- Exposure duration: 48 - 72 h, 37°C
NUMBER OF REPLICATIONS: 3
DETERMINATION OF CYTOTOXICITY
- Method: reduction in revertant colonies and/or diminution of background lawn - Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not specified
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not specified
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: Precipitation of the test compound an the plates was not observed.
COMPARISON WITH HISTORICAL CONTROL DATA:
The number of spontaneous revertants observed using each of the five strains was close to these previously established in our laboratory and was within the range obtained by Ames et al. (1975) as well as reported by De Serres and Shelby (1979). Similarly, the results with the positive control substances confirmed the known reversion properties and specificity of the tester strains as well as the full activity of the metabolizing system.
ADDITIONAL INFORMATION ON CYTOTOXICITY:
Without S9-mix: NEROL SUPRA was bacteriotoxic towards all strains at 1500 µg/plate.
WithS9-mix: NEROL SUPRA was bacteriotoxic towards the strains TA100 and TA102 at 1500 µg/plate and towards the strains TA98, TA1535, and TA1537 at 5000 µg/plate. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Guideline study (OECD) acc. to GLP, with limitations acc. to current standart protocols
- Justification for type of information:
- ANALOGUE APPROACH
1. HYPOTHESIS FOR THE ANALOGUE APPROACH
This read-across is based on the hypothesis that source substances and target substance have similar physical-chemical properties and (eco)toxicological properties because they are either stereoisomers of the target substance, are hydrolysed to the same substance or their chemical structure differs only by an additional double bond. This prediction is supported by data on the substances themselves.
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
The target substance, L-Citronellol, is a mono-constituent substance (EC No. 231-415-7, CAS no. 7540-51-4 consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and a hydroxyl group. The substance is optically active, comprising a single, pure enantiomeric laevo form.
The source substance, DL-Citronellol, is a mono-constituent substance (EC No. 203-375-0, CAS no. 106-22-9, consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and a hydroxyl group. The substance is an equimolar mixture of two optical isomers (enantiomers).
The source substance, citronellyl acetate, is a mono-constituent substance (EC No. 205-775-0, CAS no. 150-84-5) consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and an acetate group.
The source substance, geraniol and it’s isomer, consist of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. The only difference between the isomers is the position of the first double bond.
The source substance, geraniol and nerol, is a multi-constituent substance of E/Z isomers (EC No. 906-125-5). The constituents consist of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group.
The source substance, geraniol, is a mono-constituent substance (EC No. 203-377-1, CAS no. 106-24-1), consisting of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. Geraniol is a pure form of the E-isomer.
The source substance, nerol, is a mono-constituent substance (EC No. 203-378-7, CAS no. 106-25-2), consisting of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. Nerol is a pure form of the Z-isomer.
The source and target substances are both of high purity with a low concentration of impurities.
3. ANALOGUE APPROACH JUSTIFICATION
The read across hypothesis is based on structural similarity where the source substances only differ in the enantiomeric ratio or an additional double bond. Another source substance is expected to be hydrolysed to the same structure as the target substance.
In a non-chiral environment the target and source chemical DL-Citronellol will have identical properties, but in the chiral environment of living organisms the enantiomers may possess different carcinogenicity and teratogenicity (in a chiral environment, stereoisomers might experience selective absorption, protein binding, transport, enzyme interactions and metabolism, receptor interactions, and DNA binding). All endpoints read-across from DL-Citronellol are considered to be acceptable for this substance assuming that 50% of the target compound is available in the test material.
The source substance citronellyl acetate is read-across from as part of a weight of evidence approach in the repeated dose toxicity endpoint. As this substance is hydrolysed to Citronellol within 2 hours, this read-across endpoint is acceptable in the weight of evidence approach used.
The source substances geraniol, nerol and the reaction mass of geraniol/nerol differ from the target substance only by an additional double bond at C2. These structures are considered to represent a worst case scenario due to the additional potential reactive feature of the second double bond. The genotoxicity, repeated dose and reproductive toxicity endpoints read-across from these substances are therefore acceptable as a worst case assumption.
4. DATA MATRIX
Please refer to the data matrix included in the read-across justification document attached in Section 13.2. - Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- yes
- Remarks:
- analytical investigations (stability of the test substance in the carrier) were not carried out; only 4 strains tested
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Version / remarks:
- EEC Directive 84/449, B14
- GLP compliance:
- yes
- Remarks:
- Department of Toxicology, BASF AG
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- His operon
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 fraction from Aroclor induced Sprague-Dawley rats
- Test concentrations with justification for top dose:
- 0.8 - 5000 µg/plate - SPT: TA100, TA98;
0.8 - 500 µg/plate - SPT: TA1535, TA1537, PIT: all tester strains
SPT = standard plate test
PIT = preincubation test - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: complete solubility of the test substance in DMSO - Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- yes
- Remarks:
- sterility control
- Positive controls:
- yes
- Positive control substance:
- other: 2-aminoanthracene, 10 µg/plate in DMSO; TA 1535, TA 1537, TA 98 and TA 100
- Remarks:
- with metabolic activation
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- yes
- Remarks:
- sterility control
- Positive controls:
- yes
- Positive control substance:
- N-ethyl-N-nitro-N-nitrosoguanidine
- Remarks:
- without metabolic activation Migrated to IUCLID6: 5 µg/plate, in DMSO; TA 100 and TA 1535
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- yes
- Remarks:
- sterility control
- Positive controls:
- yes
- Positive control substance:
- other: 4-nitro-o-phenylendiamine; 10 µg, in DMSO; TA 98
- Remarks:
- without metabolic activation
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- yes
- Remarks:
- sterility control
- Positive controls:
- yes
- Positive control substance:
- 9-aminoacridine
- Remarks:
- without metabolic activation Migrated to IUCLID6: 100 µg/plate, in DMSO; TA 1537
- Details on test system and experimental conditions:
- positive control substances:
2-AA: 2-aminoanthracene
MNNG: N-methyl-N'-nitro-N-nitroso-guanidine
NPD: 4-nitro-o-phenylendiamine
AAC: 9-aminoacridine
1st experiment:
An SPT with TA 98 and TA 100 showed, that citronellol conentrations >500 µg/plate were cytotoxic.
2nd experiment:
In the second STP with all tester strains concentrations were adapted with 500 µg/plate being the highest concentration.
3rd experiment:
An PIT with all strains and the adapted concentrations was performed. Since in the second SPT colony scoring of TA 98 was not possible due to contamination, the SPT with this strain was repeated additional to the PIT. - Evaluation criteria:
- In general, a substance to be characterized as positive in the Ames test has to fulfill the following requirements:
- doubling of the spontaneous mutation rate (control)
- dose-response relationship
- reproducibility of the results - Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- other: bacteriotoxic effect at doses >= 500 µg/plate
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative - Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions
- Justification for type of information:
- ANALOGUE APPROACH
1. HYPOTHESIS FOR THE ANALOGUE APPROACH
This read-across is based on the hypothesis that source substances and target substance have similar physical-chemical properties and (eco)toxicological properties because they are either stereoisomers of the target substance, are hydrolysed to the same substance or their chemical structure differs only by an additional double bond. This prediction is supported by data on the substances themselves.
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
The target substance, L-Citronellol, is a mono-constituent substance (EC No. 231-415-7, CAS no. 7540-51-4 consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and a hydroxyl group. The substance is optically active, comprising a single, pure enantiomeric laevo form.
The source substance, DL-Citronellol, is a mono-constituent substance (EC No. 203-375-0, CAS no. 106-22-9, consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and a hydroxyl group. The substance is an equimolar mixture of two optical isomers (enantiomers).
The source substance, citronellyl acetate, is a mono-constituent substance (EC No. 205-775-0, CAS no. 150-84-5) consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and an acetate group.
The source substance, geraniol and it’s isomer, consist of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. The only difference between the isomers is the position of the first double bond.
The source substance, geraniol and nerol, is a multi-constituent substance of E/Z isomers (EC No. 906-125-5). The constituents consist of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group.
The source substance, geraniol, is a mono-constituent substance (EC No. 203-377-1, CAS no. 106-24-1), consisting of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. Geraniol is a pure form of the E-isomer.
The source substance, nerol, is a mono-constituent substance (EC No. 203-378-7, CAS no. 106-25-2), consisting of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. Nerol is a pure form of the Z-isomer.
The source and target substances are both of high purity with a low concentration of impurities.
3. ANALOGUE APPROACH JUSTIFICATION
The read across hypothesis is based on structural similarity where the source substances only differ in the enantiomeric ratio or an additional double bond. Another source substance is expected to be hydrolysed to the same structure as the target substance.
In a non-chiral environment the target and source chemical DL-Citronellol will have identical properties, but in the chiral environment of living organisms the enantiomers may possess different carcinogenicity and teratogenicity (in a chiral environment, stereoisomers might experience selective absorption, protein binding, transport, enzyme interactions and metabolism, receptor interactions, and DNA binding). All endpoints read-across from DL-Citronellol are considered to be acceptable for this substance assuming that 50% of the target compound is available in the test material.
The source substance citronellyl acetate is read-across from as part of a weight of evidence approach in the repeated dose toxicity endpoint. As this substance is hydrolysed to Citronellol within 2 hours, this read-across endpoint is acceptable in the weight of evidence approach used.
The source substances geraniol, nerol and the reaction mass of geraniol/nerol differ from the target substance only by an additional double bond at C2. These structures are considered to represent a worst case scenario due to the additional potential reactive feature of the second double bond. The genotoxicity, repeated dose and reproductive toxicity endpoints read-across from these substances are therefore acceptable as a worst case assumption.
4. DATA MATRIX
Please refer to the data matrix included in the read-across justification document attached in Section 13.2. - Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- other: NTP standard protocol
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Principles of method if other than guideline:
- Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res. 2000 Nov 20;455(1-2):29-60.
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- His operon
- Species / strain / cell type:
- S. typhimurium TA 97
- Species / strain / cell type:
- S. typhimurium TA 98
- Species / strain / cell type:
- S. typhimurium TA 100
- Species / strain / cell type:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Metabolic activation system:
- induced male Sprague Dawley rat liver S9 and induced male Syrian hamster liver S9
- Test concentrations with justification for top dose:
- 0, 1, 3, 10, 33, 100, 333 µg/ plate
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Untreated negative controls:
- not specified
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- other: 2-aminoanthracene; TA 97, TA 98, TA 100, TA 1535
- Remarks:
- with metabolic activation
- Untreated negative controls:
- not specified
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- 2-nitrofluorene
- Remarks:
- without metabolic activation Migrated to IUCLID6: TA 98
- Untreated negative controls:
- not specified
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- Remarks:
- without metabolic activation Migrated to IUCLID6: TA100 and TA1535
- Untreated negative controls:
- not specified
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- 9-aminoacridine
- Remarks:
- without metabolic activation Migrated to IUCLID6: TA 97
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: preincubation
DURATION
- Preincubation period: 20 minutes
- Exposure duration: usually 2 days - Evaluation criteria:
- Pattern and the strength of the mutant response are taken into account in determining the mutagenicity of a chemical. All observed responses are verified in repeat tests. If no increase in mutant colonies is seen after testing several strains under several different culture conditions, the test chemical is considered to be nonmutagenic in the Ames test.
- Species / strain:
- S. typhimurium, other: TA 97, TA 98, TA 100, TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- at 333 µg/plate
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not specified
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: observed at 333 mg/plate - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: acceptable, well documented publication
- Justification for type of information:
- ANALOGUE APPROACH
1. HYPOTHESIS FOR THE ANALOGUE APPROACH
This read-across is based on the hypothesis that source substances and target substance have similar physical-chemical properties and (eco)toxicological properties because they are either stereoisomers of the target substance, are hydrolysed to the same substance or their chemical structure differs only by an additional double bond. This prediction is supported by data on the substances themselves.
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
The target substance, L-Citronellol, is a mono-constituent substance (EC No. 231-415-7, CAS no. 7540-51-4 consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and a hydroxyl group. The substance is optically active, comprising a single, pure enantiomeric laevo form.
The source substance, DL-Citronellol, is a mono-constituent substance (EC No. 203-375-0, CAS no. 106-22-9, consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and a hydroxyl group. The substance is an equimolar mixture of two optical isomers (enantiomers).
The source substance, citronellyl acetate, is a mono-constituent substance (EC No. 205-775-0, CAS no. 150-84-5) consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and an acetate group.
The source substance, geraniol and it’s isomer, consist of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. The only difference between the isomers is the position of the first double bond.
The source substance, geraniol and nerol, is a multi-constituent substance of E/Z isomers (EC No. 906-125-5). The constituents consist of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group.
The source substance, geraniol, is a mono-constituent substance (EC No. 203-377-1, CAS no. 106-24-1), consisting of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. Geraniol is a pure form of the E-isomer.
The source substance, nerol, is a mono-constituent substance (EC No. 203-378-7, CAS no. 106-25-2), consisting of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. Nerol is a pure form of the Z-isomer.
The source and target substances are both of high purity with a low concentration of impurities.
3. ANALOGUE APPROACH JUSTIFICATION
The read across hypothesis is based on structural similarity where the source substances only differ in the enantiomeric ratio or an additional double bond. Another source substance is expected to be hydrolysed to the same structure as the target substance.
In a non-chiral environment the target and source chemical DL-Citronellol will have identical properties, but in the chiral environment of living organisms the enantiomers may possess different carcinogenicity and teratogenicity (in a chiral environment, stereoisomers might experience selective absorption, protein binding, transport, enzyme interactions and metabolism, receptor interactions, and DNA binding). All endpoints read-across from DL-Citronellol are considered to be acceptable for this substance assuming that 50% of the target compound is available in the test material.
The source substance citronellyl acetate is read-across from as part of a weight of evidence approach in the repeated dose toxicity endpoint. As this substance is hydrolysed to Citronellol within 2 hours, this read-across endpoint is acceptable in the weight of evidence approach used.
The source substances geraniol, nerol and the reaction mass of geraniol/nerol differ from the target substance only by an additional double bond at C2. These structures are considered to represent a worst case scenario due to the additional potential reactive feature of the second double bond. The genotoxicity, repeated dose and reproductive toxicity endpoints read-across from these substances are therefore acceptable as a worst case assumption.
4. DATA MATRIX
Please refer to the data matrix included in the read-across justification document attached in Section 13.2. - Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- chromosomal abberration tests in vitro using a Chinese hamster fibroblast cell line
- GLP compliance:
- not specified
- Type of assay:
- in vitro mammalian chromosome aberration test
- Species / strain / cell type:
- other: CHL cells 1-164
- Metabolic activation:
- without
- Test concentrations with justification for top dose:
- 0.0313, 0.0625, 0.125 mg/ml
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 24 h or 48 h
- Fixation time (start of exposure up to fixation or harvest of cells): 2 h
SPINDLE INHIBITOR (cytogenetic assays): colcemid, 0.2 µg/ml
STAIN (for cytogenetic assays): Giemsa
NUMBER OF CELLS EVALUATED: 100 - Evaluation criteria:
- - The results were considered negative if the incidence of aberrations was less than 4.9%, equivocal if it was between 5.0 and 9.9%, and positive if it was more than 10.0%.
- When dose-response relationships were not found, additional experiments were carried out at similar dose levels. - Statistics:
- - For a quantitative evaluation of the clastogenic potential of positive samples, the D20 (dose in mg/ml at which structural aberrations (including gaps) were detected in 20% of metaphases observed) was determined.
- Additionally, the TR value (indicates frequency of cells with exchange-type aberrations per unit dose (mg/ml)) was calculated.
- A high TR value exists for chemicals that show carcinogenic potential in animals. - Species / strain:
- other: CHL cells 1-164
- Metabolic activation:
- without
- Genotoxicity:
- ambiguous
- Cytotoxicity / choice of top concentrations:
- not specified
- Vehicle controls validity:
- not specified
- Untreated negative controls validity:
- not specified
- Positive controls validity:
- not specified
- Conclusions:
- Interpretation of results (migrated information):
ambiguous - Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: acceptable, well documented publication
- Justification for type of information:
- ANALOGUE APPROACH
1. HYPOTHESIS FOR THE ANALOGUE APPROACH
This read-across is based on the hypothesis that source substances and target substance have similar physical-chemical properties and (eco)toxicological properties because they are either stereoisomers of the target substance, are hydrolysed to the same substance or their chemical structure differs only by an additional double bond. This prediction is supported by data on the substances themselves.
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
The target substance, L-Citronellol, is a mono-constituent substance (EC No. 231-415-7, CAS no. 7540-51-4 consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and a hydroxyl group. The substance is optically active, comprising a single, pure enantiomeric laevo form.
The source substance, DL-Citronellol, is a mono-constituent substance (EC No. 203-375-0, CAS no. 106-22-9, consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and a hydroxyl group. The substance is an equimolar mixture of two optical isomers (enantiomers).
The source substance, citronellyl acetate, is a mono-constituent substance (EC No. 205-775-0, CAS no. 150-84-5) consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and an acetate group.
The source substance, geraniol and it’s isomer, consist of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. The only difference between the isomers is the position of the first double bond.
The source substance, geraniol and nerol, is a multi-constituent substance of E/Z isomers (EC No. 906-125-5). The constituents consist of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group.
The source substance, geraniol, is a mono-constituent substance (EC No. 203-377-1, CAS no. 106-24-1), consisting of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. Geraniol is a pure form of the E-isomer.
The source substance, nerol, is a mono-constituent substance (EC No. 203-378-7, CAS no. 106-25-2), consisting of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. Nerol is a pure form of the Z-isomer.
The source and target substances are both of high purity with a low concentration of impurities.
3. ANALOGUE APPROACH JUSTIFICATION
The read across hypothesis is based on structural similarity where the source substances only differ in the enantiomeric ratio or an additional double bond. Another source substance is expected to be hydrolysed to the same structure as the target substance.
In a non-chiral environment the target and source chemical DL-Citronellol will have identical properties, but in the chiral environment of living organisms the enantiomers may possess different carcinogenicity and teratogenicity (in a chiral environment, stereoisomers might experience selective absorption, protein binding, transport, enzyme interactions and metabolism, receptor interactions, and DNA binding). All endpoints read-across from DL-Citronellol are considered to be acceptable for this substance assuming that 50% of the target compound is available in the test material.
The source substance citronellyl acetate is read-across from as part of a weight of evidence approach in the repeated dose toxicity endpoint. As this substance is hydrolysed to Citronellol within 2 hours, this read-across endpoint is acceptable in the weight of evidence approach used.
The source substances geraniol, nerol and the reaction mass of geraniol/nerol differ from the target substance only by an additional double bond at C2. These structures are considered to represent a worst case scenario due to the additional potential reactive feature of the second double bond. The genotoxicity, repeated dose and reproductive toxicity endpoints read-across from these substances are therefore acceptable as a worst case assumption.
4. DATA MATRIX
Please refer to the data matrix included in the read-across justification document attached in Section 13.2. - Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- in vitro cytogenetic assay in Chinese hamster ovary cells (CHO-K1)
- GLP compliance:
- not specified
- Type of assay:
- sister chromatid exchange assay in mammalian cells
- Species / strain / cell type:
- other: Chinese hamster CHO-K1 cells
- Metabolic activation:
- without
- Test concentrations with justification for top dose:
- 0; 33,3; 100; 333; 1000 µM
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 21 h
- Selection time (if incubation with a selection agent): 21 h
SELECTION AGENT (mutation assays): mitomycin C
SPINDLE INHIBITOR (cytogenetic assays): colchicine, 50 g/ml, 2 h
STAIN (for cytogenetic assays): Giemsa
NUMBER OF REPLICATIONS: 3
NUMBER OF CELLS EVALUATED: 50 metaphases /culture - Species / strain:
- Chinese hamster Ovary (CHO)
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- other: at 1000 µM
- Conclusions:
- Interpretation of results (migrated information):
negative - Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: guideline study according to GLP
- Justification for type of information:
- ANALOGUE APPROACH
1. HYPOTHESIS FOR THE ANALOGUE APPROACH
This read-across is based on the hypothesis that source substances and target substance have similar physical-chemical properties and (eco)toxicological properties because they are either stereoisomers of the target substance, are hydrolysed to the same substance or their chemical structure differs only by an additional double bond. This prediction is supported by data on the substances themselves.
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
The target substance, L-Citronellol, is a mono-constituent substance (EC No. 231-415-7, CAS no. 7540-51-4 consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and a hydroxyl group. The substance is optically active, comprising a single, pure enantiomeric laevo form.
The source substance, DL-Citronellol, is a mono-constituent substance (EC No. 203-375-0, CAS no. 106-22-9, consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and a hydroxyl group. The substance is an equimolar mixture of two optical isomers (enantiomers).
The source substance, citronellyl acetate, is a mono-constituent substance (EC No. 205-775-0, CAS no. 150-84-5) consisting of a C8 carbon backbone, methyl substituents at C3 and C7, one double bond and an acetate group.
The source substance, geraniol and it’s isomer, consist of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. The only difference between the isomers is the position of the first double bond.
The source substance, geraniol and nerol, is a multi-constituent substance of E/Z isomers (EC No. 906-125-5). The constituents consist of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group.
The source substance, geraniol, is a mono-constituent substance (EC No. 203-377-1, CAS no. 106-24-1), consisting of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. Geraniol is a pure form of the E-isomer.
The source substance, nerol, is a mono-constituent substance (EC No. 203-378-7, CAS no. 106-25-2), consisting of a C8 carbon backbone, methyl substituents at C3 and C7, two double bonds and a hydroxyl group. Nerol is a pure form of the Z-isomer.
The source and target substances are both of high purity with a low concentration of impurities.
3. ANALOGUE APPROACH JUSTIFICATION
The read across hypothesis is based on structural similarity where the source substances only differ in the enantiomeric ratio or an additional double bond. Another source substance is expected to be hydrolysed to the same structure as the target substance.
In a non-chiral environment the target and source chemical DL-Citronellol will have identical properties, but in the chiral environment of living organisms the enantiomers may possess different carcinogenicity and teratogenicity (in a chiral environment, stereoisomers might experience selective absorption, protein binding, transport, enzyme interactions and metabolism, receptor interactions, and DNA binding). All endpoints read-across from DL-Citronellol are considered to be acceptable for this substance assuming that 50% of the target compound is available in the test material.
The source substance citronellyl acetate is read-across from as part of a weight of evidence approach in the repeated dose toxicity endpoint. As this substance is hydrolysed to Citronellol within 2 hours, this read-across endpoint is acceptable in the weight of evidence approach used.
The source substances geraniol, nerol and the reaction mass of geraniol/nerol differ from the target substance only by an additional double bond at C2. These structures are considered to represent a worst case scenario due to the additional potential reactive feature of the second double bond. The genotoxicity, repeated dose and reproductive toxicity endpoints read-across from these substances are therefore acceptable as a worst case assumption.
4. DATA MATRIX
Please refer to the data matrix included in the read-across justification document attached in Section 13.2. - Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- yes
- Remarks:
- no preincubation method performed
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- His operon
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Species / strain / cell type:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 liver homogenate from Aroclor 1254 pretreated male rats
- Test concentrations with justification for top dose:
- - Prescreen: 5 - 5000 µg/plate
- Test: 5, 15, 50, 150, 500, 1500, 5000 µg/plate - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- 2-nitrofluorene
- Remarks:
- without metabolic activation Migrated to IUCLID6: 2.5 µg/plate (TA98) in DMSO
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- Remarks:
- without metabolic activation Migrated to IUCLID6: 0.7 µg/plate (TA100, TA1535) in water
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- 9-aminoacridine
- Remarks:
- without metabolic activation Migrated to IUCLID6: 50 µg/plate (TA1537) in water
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- mitomycin C
- Remarks:
- without metabolic activation Migrated to IUCLID6: 0.15 µg/plate (TA102) in water
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- other: 2-aminoanthracene, 0.8 µg/plate (TA98, TA100, TA102, TA1535), 1.7 µg/plate (TA1537) in DMSO
- Remarks:
- with metabolic activation
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in agar (plate incorporation)
DURATION
- Exposure duration: 48 - 72 h, 37°C
NUMBER OF REPLICATIONS: 3
DETERMINATION OF CYTOTOXICITY
- Method: reduction in revertant colonies and/or diminution of background lawn - Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not specified
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not specified
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: Precipitation of the test compound an the plates was not observed.
COMPARISON WITH HISTORICAL CONTROL DATA:
The number of spontaneous revertants observed using each of the five strains was close to these previously established in our laboratory and was within the range obtained by Ames et al. (1975) as well as reported by De Serres and Shelby (1979). Similarly, the results with the positive control substances confirmed the known reversion properties and specificity of the tester strains as well as the full activity of the metabolizing system.
ADDITIONAL INFORMATION ON CYTOTOXICITY:
Without S9-mix: NEROL SUPRA was bacteriotoxic towards all strains at 1500 µg/plate.
WithS9-mix: NEROL SUPRA was bacteriotoxic towards the strains TA100 and TA102 at 1500 µg/plate and towards the strains TA98, TA1535, and TA1537 at 5000 µg/plate. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
Referenceopen allclose all
Tabel 1: Standard Plate Test, Strain TA 100
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 129 | 126 | 7 | 106 | 118 | 10 | 20 | 1.0 | 1.0 |
131 | 125 | 30 | |||||||
118 | 123 | 11 | |||||||
20 | 143 | 131 | 10 | 156 | 137 | 20 | 1.0 | 1.2 | |
127 | 116 | ||||||||
124 | 140 | ||||||||
100 | 102 | 114 | 12 | 116 | 134 | 15 | 0.9 | 1.1 | |
115 | 141 | ||||||||
126 | 144 | ||||||||
500 | B | - | - | 57 | 73 | 14 | - | 0.6 | |
B | 80 | ||||||||
B | 81 | ||||||||
2500 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0.0 |
0 | 0 | 0 | |||||||
0 | 0 | 0 | |||||||
5000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0.0 |
0 | 0 | ||||||||
0 | 0 | ||||||||
pos. control 2 -AA [10] | 1900 | 1723 | 204 | 14.6 | |||||
1500 | |||||||||
1770 | |||||||||
pos. control MNNG [5] | 1620 | 1523 | 84 | 12.1 | |||||
1480 | |||||||||
1470 |
*: S9 -fraction/cofactors = 1:9; B: reduced his- background
Table 2: Standard Plate Test, Strain TA 98
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 23 | 25 | 2 | 40 | 41 | 2 | 31 | 1.0 | 1.0 |
25 | 41 | 20 | |||||||
26 | 43 | 21 | |||||||
20 | 26 | 25 | 1 | 46 | 47 | 1 | 1.0 | 1.1 | |
24 | 47 | ||||||||
25 | 48 | ||||||||
100 | 21 | 23 | 5 | 46 | 36 | 12 | 0.9 | 0.9 | |
28 | 38 | ||||||||
19 | 23 | ||||||||
500 | 15 | 17 | 2 | 18 | 17 | 4 | 0.7 | 0.4 | |
18 | 13 | ||||||||
17 | 20 | ||||||||
2500 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0.0 |
0 | 0 | 0 | |||||||
0 | 0 | 0 | |||||||
5000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0.0 |
0 | 0 | ||||||||
0 | 0 | ||||||||
pos. control 2 -AA [10] | 1530 | 1607 | 108 | 38.9 | |||||
1730 | |||||||||
1560 | |||||||||
pos. control NPD [10] | 1250 | 1243 | 140 | 50.4 | |||||
1380 | |||||||||
1100 |
*: S9 -fraction/cofactors = 1:9
Table 3: Standard Plate Test, Strain TA 1535
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 16 | 14 | 2 | 12 | 16 | 6 | 16 | 1.0 | 1.0 |
13 | 13 | 11 | |||||||
13 | 23 | 16 | |||||||
0.8 | 12 | 16 | 4 | 17 | 15 | 2 | 1.2 | 1.0 | |
17 | 16 | ||||||||
20 | 13 | ||||||||
4 | 19 | 18 | 4 | 8 | 13 | 4 | 1.3 | 0.8 | |
14 | 16 | ||||||||
22 | 15 | ||||||||
20 | 20 | 20 | 2 | 12 | 13 | 1 | 1.4 | 0.8 | |
18 | 13 | ||||||||
21 | 14 | ||||||||
100 | 21 | 20 | 1 | 8 | 17 | 8 | 22 | 1.4 | 1.0 |
19 | 22 | 21 | |||||||
19 | 20 | 20 | |||||||
500 | 11 | 13 | 3 | 12 | 14 | 2 | 15 | 0.9 | 0.9 |
11 | 15 | 11 | |||||||
16 | 14 | 12 | |||||||
pos. control 2 -AA [10] | 160 | 200 | 67 | 12.5 | |||||
162 | |||||||||
277 | |||||||||
pos. control MNNG [5] | 1250 | 1260 | 10 | 90.0 | |||||
1270 | |||||||||
1260 |
*: S9 -fraction/cofactors = 1:9
Table 4: Standard Plate Test, Strain TA 100
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 111 | 106 | 6 | 132 | 129 | 3 | 20 | 1.0 | 1.0 |
109 | 127 | 11 | |||||||
99 | 129 | 35 | |||||||
0.8 | 94 | 97 | 3 | 144 | 137 | 6 | 0.9 | 1.1 | |
100 | 133 | ||||||||
97 | 133 | ||||||||
4 | 103 | 115 | 11 | 115 | 114 | 11 | 1.1 | 0.9 | |
124 | 125 | ||||||||
119 | 103 | ||||||||
20 | 117 | 114 | 6 | 149 | 126 | 21 | 1.1 | 1.0 | |
107 | 120 | ||||||||
118 | 109 | ||||||||
100 | 107 | 112 | 6 | 108 | 129 | 18 | 14 | 1.1 | 1.0 |
109 | 135 | 18 | |||||||
119 | 143 | 12 | |||||||
500 | 120 | 108 | 12 | 120 | 109 | 12 | 14 | 1.0 | 0.8 |
97 | 97 | 10 | |||||||
107 | 110 | 10 | |||||||
pos. control 2 -AA [10] | 1010 | 1105 | 85 | 8.5 | |||||
1130 | |||||||||
1175 | |||||||||
pos. control MNNG [5] | 1340 | 1197 | 127 | 11.3 | |||||
1150 | |||||||||
1100 |
*: S9 -fraction/cofactors = 1:9
Table 5: Standard Plate Test, Strain TA 1537
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 19 | 11 | 7 | 9 | 12 | 2 | 14 | 1.0 | 1.0 |
7 | 13 | 18 | |||||||
8 | 13 | 19 | |||||||
0.8 | 8 | 8 | 1 | 16 | 12 | 5 | 0.7 | 1.1 | |
9 | 14 | ||||||||
7 | 7 | ||||||||
4 | 11 | 9 | 6 | 11 | 10 | 2 | 0.8 | 0.8 | |
14 | 10 | ||||||||
2 | 8 | ||||||||
20 | 7 | 8 | 3 | 14 | 13 | 2 | 0.7 | 1.1 | |
5 | 10 | ||||||||
11 | 14 | ||||||||
100 | 9 | 11 | 2 | 14 | 11 | 3 | 5 | 1.0 | 0.9 |
13 | 10 | 3 | |||||||
11 | 8 | 7 | |||||||
500 | 13 | 12 | 2 | 9 | 8 | 1 | 6 | 1.0 | 0.7 |
9 | 8 | 5 | |||||||
13 | 8 | 8 | |||||||
pos. control 2 -AA [10] | 300 | 265 | 34 | 22.7 | |||||
233 | |||||||||
261 | |||||||||
pos. control AAC [100] | 374 | 464 | 95 | 40.9 | |||||
455 | |||||||||
563 |
*: S9 -fraction/cofactors = 1:9
Table 6: Preincubation Test, Strain TA 1535
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 15 | 17 | 3 | 13 | 15 | 2 | 14 | 1.0 | 1.0 |
16 | 16 | 16 | |||||||
21 | 16 | 10 | |||||||
0.8 | 21 | 21 | 2 | 22 | 21 | 6 | 1.2 | 1.4 | |
22 | 15 | ||||||||
19 | 26 | ||||||||
4 | 27 | 24 | 4 | 17 | 17 | 1 | 1.4 | 1.1 | |
25 | 17 | ||||||||
19 | 16 | ||||||||
20 | 26 | 25 | 1 | 18 | 18 | 2 | 1.4 | 1.3 | |
24 | 21 | ||||||||
24 | 19 | ||||||||
100 | 22 | 21 | 4 | 14 | 16 | 4 | 5 | 1.2 | 1.1 |
17 | 14 | 8 | |||||||
24 | 21 | 2 | |||||||
500 | B | 0 | 0 | B | - | - | 0 | 0.0 | - |
0 | B | 0 | |||||||
0 | B | 0 | |||||||
pos. control 2 -AA [10] | 134 | 170 | 33 | 11.4 | |||||
198 | |||||||||
179 | |||||||||
pos. control MNNG [5] | 851 | 814 | 49 | 47.0 | |||||
832 | |||||||||
759 |
*: S9 -fraction/cofactors = 1:9; B: reduced his- background
Table 7: Preincubation Test, Strain TA 100
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 112 | 11 | 6 | 102 | 105 | 5 | 27 | 1.0 | 1.0 |
116 | 111 | 19 | |||||||
104 | 102 | 23 | |||||||
0.8 | 90 | 96 | 15 | 122 | 121 | 7 | 0.9 | 1.1 | |
84 | 113 | ||||||||
113 | 127 | ||||||||
4 | 116 | 117 | 11 | 159 | 150 | 8 | 1.1 | 1.4 | |
107 | 143 | ||||||||
128 | 149 | ||||||||
20 | 129 | 127 | 14 | 111 | 108 | 4 | 1.1 | 1.0 | |
112 | 110 | ||||||||
139 | 103 | ||||||||
100 | 113 | 124 | 9 | 118 | 110 | 9 | 3 | 1.1 | 1.1 |
129 | 113 | 8 | |||||||
129 | 100 | 2 | |||||||
500 | 0 | 0 | 0 | B | - | - | 0 | 0.0 | - |
0 | B | 0 | |||||||
0 | B | 0 | |||||||
pos. control 2 -AA [10] | 848 | 1133 | 341 | 10.8 | |||||
1040 | |||||||||
1510 | |||||||||
pos. control MNNG [5] | 684 | 675 | 10 | 6.1 | |||||
676 | |||||||||
664 |
*: S9 -fraction/cofactors = 1:9; B: reduced his- background
Table 8: Preincubation Test, Strain TA 1537
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 11 | 9 | 2 | 11 | 11 | 1 | 3 | 1.0 | 1.0 |
7 | 12 | 2 | |||||||
10 | 10 | 4 | |||||||
0.8 | 14 | 12 | 4 | 5 | 10 | 5 | 1.3 | 0.9 | |
7 | 14 | ||||||||
14 | 10 | ||||||||
4 | 7 | 8 | 2 | 11 | 11 | 2 | 0.9 | 1.0 | |
7 | 9 | ||||||||
10 | 13 | ||||||||
20 | 10 | 8 | 2 | 10 | 10 | 3 | 0.8 | 0.9 | |
7 | 13 | ||||||||
6 | 7 | ||||||||
100 | 13 | 12 | 3 | 12 | 9 | 3 | 4 | 1.3 | 0.8 |
14 | 7 | 3 | |||||||
8 | 8 | 6 | |||||||
500 | 0 | 0 | 0 | B | - | - | 0 | 0.0 | - |
0 | B | 0 | |||||||
0 | B | 0 | |||||||
pos. control 2 -AA [10] | 119 | 116 | 9 | 10.5 | |||||
123 | |||||||||
105 | |||||||||
pos. control AAC [100] | 1200 | 1197 | 55 | 128.2 | |||||
1250 | |||||||||
1140 |
*: S9 -fraction/cofactors = 1:9; B: reduced his- background
Table 9: Preincubation Test, Strain TA 98
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 30 | 31 | 1 | 35 | 35 | 5 | 21 | 1.0 | 1.0 |
32 | 31 | 15 | |||||||
30 | 40 | 23 | |||||||
0.8 | 17 | 20 | 4 | 41 | 35 | 6 | 0.6 | 1.0 | |
24 | 30 | ||||||||
18 | 35 | ||||||||
4 | 21 | 23 | 3 | 40 | 38 | 4 | 0.7 | 1.1 | |
21 | 33 | ||||||||
26 | 40 | ||||||||
20 | 20 | 22 | 7 | 34 | 36 | 3 | 0.7 | 1.0 | |
16 | 40 | ||||||||
29 | 35 | ||||||||
100 | 14 | 20 | 6 | 30 | 31 | 3 | 0 | 0.7 | 0.9 |
24 | 28 | 0 | |||||||
23 | 34 | 0 | |||||||
500 | 0 | 0 | 0 | B | - | - | 0 | 0.0 | - |
0 | B | 0 | |||||||
0 | B | 0 | |||||||
pos. control 2 -AA [10] | 1370 | 1437 | 59 | 40.7 | |||||
1480 | |||||||||
1460 | |||||||||
pos. control NPD [10] | 1320 | 1197 | 120 | 39.0 | |||||
1190 | |||||||||
1080 |
*: S9 -fraction/cofactors = 1:9; B: reduced his- background
Table 10: Standard Plate Test, Strain TA 98
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 21 | 22 | 3 | 39 | 38 | 4 | 21 | 1.0 | 1.0 |
25 | 41 | 15 | |||||||
19 | 33 | 29 | |||||||
0.8 | 19 | 24 | 5 | 37 | 39 | 2 | 1.1 | 1.0 | |
25 | 39 | ||||||||
29 | 40 | ||||||||
4 | 26 | 27 | 1 | 31 | 33 | 2 | 1.2 | 0.9 | |
28 | 33 | ||||||||
26 | 34 | ||||||||
20 | 25 | 28 | 7 | 34 | 31 | 3 | 1.3 | 0.8 | |
22 | 28 | ||||||||
36 | 32 | ||||||||
100 | 25 | 26 | 1 | 28 | 29 | 2 | 11 | 1.2 | 0.8 |
27 | 32 | 15 | |||||||
27 | 28 | 16 | |||||||
500 | 24 | 24 | 5 | 28 | 28 | 0 | 14 | 1.1 | 0.7 |
20 | 28 | 9 | |||||||
29 | 28 | 9 | |||||||
pos. control 2 -AA [10] | 1260 | 1132 | 133 | 30.0 | |||||
995 | |||||||||
1140 | |||||||||
pos. control NPD [10] | 825 | 794 | 35 | 36.6 | |||||
801 | |||||||||
756 |
*: S9 -fraction/cofactors = 1:9
24 hour-Treatment:
Percentage of polyploid cells (%):
solvent 0
0.0313 mg/mL 2
0.0625 mg/mL 6
0.125 mg/mL 4
Cells with structural chromosome aberrations (%) (total):
solvent 0
0.0313 mg/mL 1
0.0625 mg/mL 2
0.125 mg/mL 3
48 hour-Treatment:
Percentage of polyploid cells (%):
solvent 0
0.0313 mg/mL 0
0.0625 mg/mL 4
0.125 mg/mL 8
Cells with structural chromosome aberrations (%) (total):
solvent 1
0.0313 mg/mL 0
0.0625 mg/mL 2
0.125 mg/mL 4
Tabel 1: Standard Plate Test, Strain TA 100
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 129 | 126 | 7 | 106 | 118 | 10 | 20 | 1.0 | 1.0 |
131 | 125 | 30 | |||||||
118 | 123 | 11 | |||||||
20 | 143 | 131 | 10 | 156 | 137 | 20 | 1.0 | 1.2 | |
127 | 116 | ||||||||
124 | 140 | ||||||||
100 | 102 | 114 | 12 | 116 | 134 | 15 | 0.9 | 1.1 | |
115 | 141 | ||||||||
126 | 144 | ||||||||
500 | B | - | - | 57 | 73 | 14 | - | 0.6 | |
B | 80 | ||||||||
B | 81 | ||||||||
2500 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0.0 |
0 | 0 | 0 | |||||||
0 | 0 | 0 | |||||||
5000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0.0 |
0 | 0 | ||||||||
0 | 0 | ||||||||
pos. control 2 -AA [10] | 1900 | 1723 | 204 | 14.6 | |||||
1500 | |||||||||
1770 | |||||||||
pos. control MNNG [5] | 1620 | 1523 | 84 | 12.1 | |||||
1480 | |||||||||
1470 |
*: S9 -fraction/cofactors = 1:9; B: reduced his- background
Table 2: Standard Plate Test, Strain TA 98
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 23 | 25 | 2 | 40 | 41 | 2 | 31 | 1.0 | 1.0 |
25 | 41 | 20 | |||||||
26 | 43 | 21 | |||||||
20 | 26 | 25 | 1 | 46 | 47 | 1 | 1.0 | 1.1 | |
24 | 47 | ||||||||
25 | 48 | ||||||||
100 | 21 | 23 | 5 | 46 | 36 | 12 | 0.9 | 0.9 | |
28 | 38 | ||||||||
19 | 23 | ||||||||
500 | 15 | 17 | 2 | 18 | 17 | 4 | 0.7 | 0.4 | |
18 | 13 | ||||||||
17 | 20 | ||||||||
2500 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0.0 |
0 | 0 | 0 | |||||||
0 | 0 | 0 | |||||||
5000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0.0 |
0 | 0 | ||||||||
0 | 0 | ||||||||
pos. control 2 -AA [10] | 1530 | 1607 | 108 | 38.9 | |||||
1730 | |||||||||
1560 | |||||||||
pos. control NPD [10] | 1250 | 1243 | 140 | 50.4 | |||||
1380 | |||||||||
1100 |
*: S9 -fraction/cofactors = 1:9
Table 3: Standard Plate Test, Strain TA 1535
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 16 | 14 | 2 | 12 | 16 | 6 | 16 | 1.0 | 1.0 |
13 | 13 | 11 | |||||||
13 | 23 | 16 | |||||||
0.8 | 12 | 16 | 4 | 17 | 15 | 2 | 1.2 | 1.0 | |
17 | 16 | ||||||||
20 | 13 | ||||||||
4 | 19 | 18 | 4 | 8 | 13 | 4 | 1.3 | 0.8 | |
14 | 16 | ||||||||
22 | 15 | ||||||||
20 | 20 | 20 | 2 | 12 | 13 | 1 | 1.4 | 0.8 | |
18 | 13 | ||||||||
21 | 14 | ||||||||
100 | 21 | 20 | 1 | 8 | 17 | 8 | 22 | 1.4 | 1.0 |
19 | 22 | 21 | |||||||
19 | 20 | 20 | |||||||
500 | 11 | 13 | 3 | 12 | 14 | 2 | 15 | 0.9 | 0.9 |
11 | 15 | 11 | |||||||
16 | 14 | 12 | |||||||
pos. control 2 -AA [10] | 160 | 200 | 67 | 12.5 | |||||
162 | |||||||||
277 | |||||||||
pos. control MNNG [5] | 1250 | 1260 | 10 | 90.0 | |||||
1270 | |||||||||
1260 |
*: S9 -fraction/cofactors = 1:9
Table 4: Standard Plate Test, Strain TA 100
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 111 | 106 | 6 | 132 | 129 | 3 | 20 | 1.0 | 1.0 |
109 | 127 | 11 | |||||||
99 | 129 | 35 | |||||||
0.8 | 94 | 97 | 3 | 144 | 137 | 6 | 0.9 | 1.1 | |
100 | 133 | ||||||||
97 | 133 | ||||||||
4 | 103 | 115 | 11 | 115 | 114 | 11 | 1.1 | 0.9 | |
124 | 125 | ||||||||
119 | 103 | ||||||||
20 | 117 | 114 | 6 | 149 | 126 | 21 | 1.1 | 1.0 | |
107 | 120 | ||||||||
118 | 109 | ||||||||
100 | 107 | 112 | 6 | 108 | 129 | 18 | 14 | 1.1 | 1.0 |
109 | 135 | 18 | |||||||
119 | 143 | 12 | |||||||
500 | 120 | 108 | 12 | 120 | 109 | 12 | 14 | 1.0 | 0.8 |
97 | 97 | 10 | |||||||
107 | 110 | 10 | |||||||
pos. control 2 -AA [10] | 1010 | 1105 | 85 | 8.5 | |||||
1130 | |||||||||
1175 | |||||||||
pos. control MNNG [5] | 1340 | 1197 | 127 | 11.3 | |||||
1150 | |||||||||
1100 |
*: S9 -fraction/cofactors = 1:9
Table 5: Standard Plate Test, Strain TA 1537
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 19 | 11 | 7 | 9 | 12 | 2 | 14 | 1.0 | 1.0 |
7 | 13 | 18 | |||||||
8 | 13 | 19 | |||||||
0.8 | 8 | 8 | 1 | 16 | 12 | 5 | 0.7 | 1.1 | |
9 | 14 | ||||||||
7 | 7 | ||||||||
4 | 11 | 9 | 6 | 11 | 10 | 2 | 0.8 | 0.8 | |
14 | 10 | ||||||||
2 | 8 | ||||||||
20 | 7 | 8 | 3 | 14 | 13 | 2 | 0.7 | 1.1 | |
5 | 10 | ||||||||
11 | 14 | ||||||||
100 | 9 | 11 | 2 | 14 | 11 | 3 | 5 | 1.0 | 0.9 |
13 | 10 | 3 | |||||||
11 | 8 | 7 | |||||||
500 | 13 | 12 | 2 | 9 | 8 | 1 | 6 | 1.0 | 0.7 |
9 | 8 | 5 | |||||||
13 | 8 | 8 | |||||||
pos. control 2 -AA [10] | 300 | 265 | 34 | 22.7 | |||||
233 | |||||||||
261 | |||||||||
pos. control AAC [100] | 374 | 464 | 95 | 40.9 | |||||
455 | |||||||||
563 |
*: S9 -fraction/cofactors = 1:9
Table 6: Preincubation Test, Strain TA 1535
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 15 | 17 | 3 | 13 | 15 | 2 | 14 | 1.0 | 1.0 |
16 | 16 | 16 | |||||||
21 | 16 | 10 | |||||||
0.8 | 21 | 21 | 2 | 22 | 21 | 6 | 1.2 | 1.4 | |
22 | 15 | ||||||||
19 | 26 | ||||||||
4 | 27 | 24 | 4 | 17 | 17 | 1 | 1.4 | 1.1 | |
25 | 17 | ||||||||
19 | 16 | ||||||||
20 | 26 | 25 | 1 | 18 | 18 | 2 | 1.4 | 1.3 | |
24 | 21 | ||||||||
24 | 19 | ||||||||
100 | 22 | 21 | 4 | 14 | 16 | 4 | 5 | 1.2 | 1.1 |
17 | 14 | 8 | |||||||
24 | 21 | 2 | |||||||
500 | B | 0 | 0 | B | - | - | 0 | 0.0 | - |
0 | B | 0 | |||||||
0 | B | 0 | |||||||
pos. control 2 -AA [10] | 134 | 170 | 33 | 11.4 | |||||
198 | |||||||||
179 | |||||||||
pos. control MNNG [5] | 851 | 814 | 49 | 47.0 | |||||
832 | |||||||||
759 |
*: S9 -fraction/cofactors = 1:9; B: reduced his- background
Table 7: Preincubation Test, Strain TA 100
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 112 | 11 | 6 | 102 | 105 | 5 | 27 | 1.0 | 1.0 |
116 | 111 | 19 | |||||||
104 | 102 | 23 | |||||||
0.8 | 90 | 96 | 15 | 122 | 121 | 7 | 0.9 | 1.1 | |
84 | 113 | ||||||||
113 | 127 | ||||||||
4 | 116 | 117 | 11 | 159 | 150 | 8 | 1.1 | 1.4 | |
107 | 143 | ||||||||
128 | 149 | ||||||||
20 | 129 | 127 | 14 | 111 | 108 | 4 | 1.1 | 1.0 | |
112 | 110 | ||||||||
139 | 103 | ||||||||
100 | 113 | 124 | 9 | 118 | 110 | 9 | 3 | 1.1 | 1.1 |
129 | 113 | 8 | |||||||
129 | 100 | 2 | |||||||
500 | 0 | 0 | 0 | B | - | - | 0 | 0.0 | - |
0 | B | 0 | |||||||
0 | B | 0 | |||||||
pos. control 2 -AA [10] | 848 | 1133 | 341 | 10.8 | |||||
1040 | |||||||||
1510 | |||||||||
pos. control MNNG [5] | 684 | 675 | 10 | 6.1 | |||||
676 | |||||||||
664 |
*: S9 -fraction/cofactors = 1:9; B: reduced his- background
Table 8: Preincubation Test, Strain TA 1537
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 11 | 9 | 2 | 11 | 11 | 1 | 3 | 1.0 | 1.0 |
7 | 12 | 2 | |||||||
10 | 10 | 4 | |||||||
0.8 | 14 | 12 | 4 | 5 | 10 | 5 | 1.3 | 0.9 | |
7 | 14 | ||||||||
14 | 10 | ||||||||
4 | 7 | 8 | 2 | 11 | 11 | 2 | 0.9 | 1.0 | |
7 | 9 | ||||||||
10 | 13 | ||||||||
20 | 10 | 8 | 2 | 10 | 10 | 3 | 0.8 | 0.9 | |
7 | 13 | ||||||||
6 | 7 | ||||||||
100 | 13 | 12 | 3 | 12 | 9 | 3 | 4 | 1.3 | 0.8 |
14 | 7 | 3 | |||||||
8 | 8 | 6 | |||||||
500 | 0 | 0 | 0 | B | - | - | 0 | 0.0 | - |
0 | B | 0 | |||||||
0 | B | 0 | |||||||
pos. control 2 -AA [10] | 119 | 116 | 9 | 10.5 | |||||
123 | |||||||||
105 | |||||||||
pos. control AAC [100] | 1200 | 1197 | 55 | 128.2 | |||||
1250 | |||||||||
1140 |
*: S9 -fraction/cofactors = 1:9; B: reduced his- background
Table 9: Preincubation Test, Strain TA 98
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 30 | 31 | 1 | 35 | 35 | 5 | 21 | 1.0 | 1.0 |
32 | 31 | 15 | |||||||
30 | 40 | 23 | |||||||
0.8 | 17 | 20 | 4 | 41 | 35 | 6 | 0.6 | 1.0 | |
24 | 30 | ||||||||
18 | 35 | ||||||||
4 | 21 | 23 | 3 | 40 | 38 | 4 | 0.7 | 1.1 | |
21 | 33 | ||||||||
26 | 40 | ||||||||
20 | 20 | 22 | 7 | 34 | 36 | 3 | 0.7 | 1.0 | |
16 | 40 | ||||||||
29 | 35 | ||||||||
100 | 14 | 20 | 6 | 30 | 31 | 3 | 0 | 0.7 | 0.9 |
24 | 28 | 0 | |||||||
23 | 34 | 0 | |||||||
500 | 0 | 0 | 0 | B | - | - | 0 | 0.0 | - |
0 | B | 0 | |||||||
0 | B | 0 | |||||||
pos. control 2 -AA [10] | 1370 | 1437 | 59 | 40.7 | |||||
1480 | |||||||||
1460 | |||||||||
pos. control NPD [10] | 1320 | 1197 | 120 | 39.0 | |||||
1190 | |||||||||
1080 |
*: S9 -fraction/cofactors = 1:9; B: reduced his- background
Table 10: Standard Plate Test, Strain TA 98
revertants / plate |
titer dil. | quotient |
|||||||
dose [µg/plate] | -S9 | M | SD | +S9* | M | SD | exp-6 | -S9 | +S9* |
neg. control DMSO | 21 | 22 | 3 | 39 | 38 | 4 | 21 | 1.0 | 1.0 |
25 | 41 | 15 | |||||||
19 | 33 | 29 | |||||||
0.8 | 19 | 24 | 5 | 37 | 39 | 2 | 1.1 | 1.0 | |
25 | 39 | ||||||||
29 | 40 | ||||||||
4 | 26 | 27 | 1 | 31 | 33 | 2 | 1.2 | 0.9 | |
28 | 33 | ||||||||
26 | 34 | ||||||||
20 | 25 | 28 | 7 | 34 | 31 | 3 | 1.3 | 0.8 | |
22 | 28 | ||||||||
36 | 32 | ||||||||
100 | 25 | 26 | 1 | 28 | 29 | 2 | 11 | 1.2 | 0.8 |
27 | 32 | 15 | |||||||
27 | 28 | 16 | |||||||
500 | 24 | 24 | 5 | 28 | 28 | 0 | 14 | 1.1 | 0.7 |
20 | 28 | 9 | |||||||
29 | 28 | 9 | |||||||
pos. control 2 -AA [10] | 1260 | 1132 | 133 | 30.0 | |||||
995 | |||||||||
1140 | |||||||||
pos. control NPD [10] | 825 | 794 | 35 | 36.6 | |||||
801 | |||||||||
756 |
*: S9 -fraction/cofactors = 1:9
24 hour-Treatment:
Percentage of polyploid cells (%):
solvent 0
0.0313 mg/mL 2
0.0625 mg/mL 6
0.125 mg/mL 4
Cells with structural chromosome aberrations (%) (total):
solvent 0
0.0313 mg/mL 1
0.0625 mg/mL 2
0.125 mg/mL 3
48 hour-Treatment:
Percentage of polyploid cells (%):
solvent 0
0.0313 mg/mL 0
0.0625 mg/mL 4
0.125 mg/mL 8
Cells with structural chromosome aberrations (%) (total):
solvent 1
0.0313 mg/mL 0
0.0625 mg/mL 2
0.125 mg/mL 4
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Description of key information
Genetic toxicity in vivo:
These endpoints were fulfilled using read across from a reaction mass of Nerol (cis-3,7-dimethyl-2,6-octadien-1-ol ) and Geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol). Data from tests performed with the structurally comparable compounds nerol (cis-3,7-dimethyl-2,6-octadien-1-ol) or the respective stereoisomer geraniol (trans-3,7-dimethyl-2,6-octadien-1-ol) were used to address this endpoint via read across. Inclusion of nerol/geraniol into this assessment is justified by the structural similarity with citronellol (3,7-dimethyloct-6-en-1-ol). These structures are identical except for an additional double bond found in nerol/geraniol. The structure of nerol/geraniol is considered to represent a worst case when compared to citronellol based on this second double bond as possible additional reactive feature. A putative steric hindrance to the action of cytochromes such as those present in the S9 mix due to the additional double bond is not to be expected. Furthermore, relevant physicochemical parameters show comparability between nerol/geraniol and citronellol (molecular weight of 154.2 and 156.3 ; log Pow at 2.6 and 3.41; vapour pressure of 1 and 8.6 Pa; water solubility of 769 and 307 mg/l respectively).
The reaction mass of geraniol and nerol was tested in a MNT in NMRI mice (BASF SE, 2010). For this purpose, the test substance, dissolved in DMSO and emulsified in corn oil, was administered once orally to male animals at dose levels of 375 mg/kg, 750 mg/kg and 1 500 mg/kg body weight in a volume of 10 mL/kg body weight in each case. The animals were sacrificed and the bone marrow of the two femora was prepared 24 and 48 hours after administration in the highest dose group of 1 500 mg/kg body weight and in the vehicle controls. In the test groups of 750 mg/kg and 375 mg/kg body weight and in the positive control groups, the 24-hour sacrifice interval was investigated only. After staining of the preparations, 2 000 polychromatic erythrocytes were evaluated per animal and investigated for micronuclei. The normocytes with and without micronuclei occurring per 2 000 polychromatic erythrocytes were also recorded. As vehicle control, male mice were administered merely the vehicle, DMSO/corn oil (ratio 2:3), by the same route and in the same volume as the animals of the dose groups, which gave frequencies of micronucleated polychromatic erythrocytes within the historical vehicle control data range. Both positive control substances, cyclophosphamide for clastogenicity and vincristine sulfate for spindle poison effects, led to the expected increase in the rate of polychromatic erythrocytes containing small or large micronuclei. No inhibition of erythropoiesis determined from the ratio of polychromatic to normochromatic erythrocytes was detected.
According to the results of the study, the single oral administration of the reaction mass of geraniol and nerol did not lead to any increase in the number of polychromatic erythrocytes containing either small or large micronuclei. The rate of micronuclei was within the range of the concurrent vehicle control in all dose groups and at all sacrifice intervals and within the range of the historical vehicle control data. Thus, under the experimental conditions of this study, the reaction mass of geraniol and nerol does not induce cytogenetic damage in bone marrow cells of NMRI mice in vivo.
Overall in a weight of evidence, the data of the structural analogue provide evidence for an absence of any cytogenic activity of citronellol.
Link to relevant study records
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: study according to OECD guideline and GLP
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5395 (In Vivo Mammalian Cytogenetics Tests: Erythrocyte Micronucleus Assay)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- micronucleus assay
- Species:
- mouse
- Strain:
- NMRI
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River
- Age at study initiation: 5-8 weeks
- Weight at study initiation: 28.15 g
- Assigned to test groups randomly: yes, according to a randomization plan prepared with an appropriate computer program
- Housing: single in Makrolon cages, type M II
- Diet (e.g. ad libitum): standardized pellet feed (Maus/Ratte Haltung "GLP", Provimi Kliba SA, Kaiseraugst, Switzerland)
- Water (e.g. ad libitum): drinking water from bottles, ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Air changes (per hr): fully air conditioned rooms with central air conditioning
- Photoperiod (hrs dark / hrs light): 12:12 - Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: DMSO/corn oil (ratio 2:3)
- Justification for choice of solvent/vehicle: limited solubility of test substance in water and better volume for administration
- Amount of vehicle (if gavage or dermal): 10 ml/kg bw - Duration of treatment / exposure:
- once
- Frequency of treatment:
- once
- Post exposure period:
- 24 and 48 hours
- Remarks:
- Doses / Concentrations:
375 mg/kg bw
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
750 mg/kg bw
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
1500 mg/kg bw
Basis:
actual ingested - No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- - cyclophosphamide (CPP): 20 mg/kg bw
- vincristine sulfate (VCR): 0.15 mg/kg bw - Tissues and cell types examined:
- - Clinical examinations: After treatment up to the time of sacrifice, the animals were examined for any clinically evident signs of toxicity several times.
- Preparation of the bone marrow: The bone marrow was prepared according to the method described by Schmid and Salamone et al.
- MICROSCOPIC EVALUATION
In general, 2 000 polychromatic erythrocytes (PCE) were evaluated for the occurrence of micronuclei from each animal of every test group, so in total 10 000 PCEs were scored per test group. The normochromatic erythrocytes (= normocytes / NCE) were also scored. The following parameters were recorded:
• Number of polychromatic erythrocytes
• Number of polychromatic erythrocytes containing micronuclei
The increase in the number of micronuclei in polychromatic erythrocytes of treated animals as compared with the vehicle control group provides an index of a chromosome-breaking (clastogenic) effect or damage of the mitotic apparatus (aneugenic activity) of the test substance administered.
• Number of normochromatic erythrocytes
• Number of normochromatic erythrocytes containing micronuclei
The number of micronuclei in normochromatic erythrocytes at the early sacrifice interval shows the situation before test substance administration and may serve as a control value. A test substance induced increase in the number of micronuclei in normocytes may be found with an increase in the duration of the sacrifice interval.
• Ratio of polychromatic to normochromatic erythrocytes
An alteration of this ratio indicates that the test substance actually reached the bone marrow, means the target determined for genotoxic effects.
• Number of small micronuclei (d < D/4) and of large micronuclei (d ≥ D/4)
[d = diameter of micronucleus, D = cell diameter]
The size of micronuclei may indicate the possible mode of action of the test substance, i.e. a clastogenic effect (d < D/4) or a spindle poison effect (d ≥ D/4).
Slides were coded before microscopic analysis. - Details of tissue and slide preparation:
- Preparation of the bone marrow
- The animals were anesthetized with isoflurane and afterwards sacrificed by cervical dislocation. Then the two femora were prepared by dissection and removing all soft tissues.
- After cutting off the epiphyses, the bone marrow was flushed out of the diaphysis into a centrifuge tube using a cannula filled with fetal calf serum (FCS) which was preheated up to 37°C (about 2 mL/femur).
- The suspension was mixed thoroughly with a pipette and centrifuged at 300 x g for 5 minutes. The supernatant was removed and the precipitate was resuspended in about 50 μL fresh FCS.
- One drop of this suspension was dropped onto clean microscopic slides, using a Pasteur pipette. Smears were prepared using slides with ground edges. The preparations were dried in the air and subsequently stained.
Staining of the slides
- The slides were stained with eosin and methylene blue (modified May-Grünwald solution or Wrights solution) for about 5 minutes.
- After briefly rinsing in purified water, the preparations were soaked in purified water for about 2 - 3 minutes.
- Subsequently, the slides were stained with Giemsa solution (15 mL Giemsa plus 185 mL purified water) for about 15 minutes.
- After rinsing twice in purified water and clarifying in xylene, the preparations were mounted in Corbit-Balsam. - Evaluation criteria:
- Acceptance criteria
The mouse micronucleus test is considered valid if the following criteria are met:
• The quality of the slides must allow the evaluation of a sufficient number of analyzable
cells; i. e. ≥ 2 000 PCEs per animal and a clear differentiation between PCEs and NCEs.
• The ratio of PCEs/NCEs in the concurrent vehicle control animals has to be within the normal range for the animal strain selected.
• The number of cells containing micronuclei in vehicle control animals has to be within the range of the historical vehicle control data both for PCEs and for NCEs.
• The two positive control substances have to induce a distinct increase in the number of PCEs containing small and/or large micronuclei within the range of the historical positive control data or above.
Assessment criteria
A finding is considered positive if the following criteria are met:
• Statistically significant and dose-related increase in the number of PCEs containing micronuclei.
• The number of PCEs containing micronuclei has to exceed both the concurrent vehicle control value and the range of the historical vehicle control data.
A test substance is considered negative if the following criteria are met:
• The number of cells containing micronuclei in the dose groups is not statistically significant increased above the concurrent vehicle control value and is within the range of the historical vehicle control data. - Statistics:
- The statistical evaluation of the data was carried out using the program system MUKERN (BASF SE). The asymptotic U test according to MANN-WHITNEY (modified rank test according to WILCOXON) was carried out to clarify the question whether there are statistically significant differences between the untreated control group and the treated dose groups with regard to the micronucleus rate in polychromatic erythrocytes. The relative frequencies of cells containing micronuclei of each animal were used as a criterion for the rank determination for the U test. Statistical significances were identified as follows:
* p ≤ 0.05
** p ≤ 0.01
However, both biological relevance and statistical significance were considered together. - Sex:
- male
- Genotoxicity:
- negative
- Toxicity:
- yes
- Remarks:
- piloerection and hunched posture in high dose
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- According to the results of the present study, there are no statistical significances or biologically relevant differences in the frequency of erythrocytes containing micronuclei either between the vehicle control groups and the three dose groups (375 mg/kg, 750 mg/kg and 1 500 mg/kg) or between the two sacrifice intervals (24 and 48 hours). The number of normochromatic or polychromatic erythrocytes containing small micronuclei (d < D/4) or large micronuclei (d ≥ D/4) did not deviate from the vehicle control values at any of the sacrifice intervals and was within the historical vehicle control data range.
In this study, after single oral administration of the vehicle DMSO/corn oil the ratio of PCEs/NCEs in the vehicle control animals at both sacrifice intervals was within the normal range for the animal strain selected. Besides the number of cells containing micronuclei in these vehicle control animals was within the range of the historical vehicle control data both for PCEs and for NCEs.
In addition, both positive control substances, cyclophosphamide and vincristine sulfate, induced a statistically significant increase in the number of PCEs containing small and/or large micronuclei within the range of the historical positive control data or above. - Conclusions:
- Interpretation of results: negative
According to the authors, under the experimental conditions chosen here, the test substance has no chromosome-damaging (clastogenic) effect nor does it lead to any impairment of chromosome distribution in the course of mitosis (aneugenic activity) in bone marrow cells of NMRI mice in vivo. - Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: study according to OECD guideline and GLP
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5395 (In Vivo Mammalian Cytogenetics Tests: Erythrocyte Micronucleus Assay)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- micronucleus assay
- Species:
- mouse
- Strain:
- NMRI
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River
- Age at study initiation: 5-8 weeks
- Weight at study initiation: 28.15 g
- Assigned to test groups randomly: yes, according to a randomization plan prepared with an appropriate computer program
- Housing: single in Makrolon cages, type M II
- Diet (e.g. ad libitum): standardized pellet feed (Maus/Ratte Haltung "GLP", Provimi Kliba SA, Kaiseraugst, Switzerland)
- Water (e.g. ad libitum): drinking water from bottles, ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Air changes (per hr): fully air conditioned rooms with central air conditioning
- Photoperiod (hrs dark / hrs light): 12:12 - Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: DMSO/corn oil (ratio 2:3)
- Justification for choice of solvent/vehicle: limited solubility of test substance in water and better volume for administration
- Amount of vehicle (if gavage or dermal): 10 ml/kg bw - Duration of treatment / exposure:
- once
- Frequency of treatment:
- once
- Post exposure period:
- 24 and 48 hours
- Remarks:
- Doses / Concentrations:
375 mg/kg bw
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
750 mg/kg bw
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
1500 mg/kg bw
Basis:
actual ingested - No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- - cyclophosphamide (CPP): 20 mg/kg bw
- vincristine sulfate (VCR): 0.15 mg/kg bw - Tissues and cell types examined:
- - Clinical examinations: After treatment up to the time of sacrifice, the animals were examined for any clinically evident signs of toxicity several times.
- Preparation of the bone marrow: The bone marrow was prepared according to the method described by Schmid and Salamone et al.
- MICROSCOPIC EVALUATION
In general, 2 000 polychromatic erythrocytes (PCE) were evaluated for the occurrence of micronuclei from each animal of every test group, so in total 10 000 PCEs were scored per test group. The normochromatic erythrocytes (= normocytes / NCE) were also scored. The following parameters were recorded:
• Number of polychromatic erythrocytes
• Number of polychromatic erythrocytes containing micronuclei
The increase in the number of micronuclei in polychromatic erythrocytes of treated animals as compared with the vehicle control group provides an index of a chromosome-breaking (clastogenic) effect or damage of the mitotic apparatus (aneugenic activity) of the test substance administered.
• Number of normochromatic erythrocytes
• Number of normochromatic erythrocytes containing micronuclei
The number of micronuclei in normochromatic erythrocytes at the early sacrifice interval shows the situation before test substance administration and may serve as a control value. A test substance induced increase in the number of micronuclei in normocytes may be found with an increase in the duration of the sacrifice interval.
• Ratio of polychromatic to normochromatic erythrocytes
An alteration of this ratio indicates that the test substance actually reached the bone marrow, means the target determined for genotoxic effects.
• Number of small micronuclei (d < D/4) and of large micronuclei (d ≥ D/4)
[d = diameter of micronucleus, D = cell diameter]
The size of micronuclei may indicate the possible mode of action of the test substance, i.e. a clastogenic effect (d < D/4) or a spindle poison effect (d ≥ D/4).
Slides were coded before microscopic analysis. - Details of tissue and slide preparation:
- Preparation of the bone marrow
- The animals were anesthetized with isoflurane and afterwards sacrificed by cervical dislocation. Then the two femora were prepared by dissection and removing all soft tissues.
- After cutting off the epiphyses, the bone marrow was flushed out of the diaphysis into a centrifuge tube using a cannula filled with fetal calf serum (FCS) which was preheated up to 37°C (about 2 mL/femur).
- The suspension was mixed thoroughly with a pipette and centrifuged at 300 x g for 5 minutes. The supernatant was removed and the precipitate was resuspended in about 50 μL fresh FCS.
- One drop of this suspension was dropped onto clean microscopic slides, using a Pasteur pipette. Smears were prepared using slides with ground edges. The preparations were dried in the air and subsequently stained.
Staining of the slides
- The slides were stained with eosin and methylene blue (modified May-Grünwald solution or Wrights solution) for about 5 minutes.
- After briefly rinsing in purified water, the preparations were soaked in purified water for about 2 - 3 minutes.
- Subsequently, the slides were stained with Giemsa solution (15 mL Giemsa plus 185 mL purified water) for about 15 minutes.
- After rinsing twice in purified water and clarifying in xylene, the preparations were mounted in Corbit-Balsam. - Evaluation criteria:
- Acceptance criteria
The mouse micronucleus test is considered valid if the following criteria are met:
• The quality of the slides must allow the evaluation of a sufficient number of analyzable
cells; i. e. ≥ 2 000 PCEs per animal and a clear differentiation between PCEs and NCEs.
• The ratio of PCEs/NCEs in the concurrent vehicle control animals has to be within the normal range for the animal strain selected.
• The number of cells containing micronuclei in vehicle control animals has to be within the range of the historical vehicle control data both for PCEs and for NCEs.
• The two positive control substances have to induce a distinct increase in the number of PCEs containing small and/or large micronuclei within the range of the historical positive control data or above.
Assessment criteria
A finding is considered positive if the following criteria are met:
• Statistically significant and dose-related increase in the number of PCEs containing micronuclei.
• The number of PCEs containing micronuclei has to exceed both the concurrent vehicle control value and the range of the historical vehicle control data.
A test substance is considered negative if the following criteria are met:
• The number of cells containing micronuclei in the dose groups is not statistically significant increased above the concurrent vehicle control value and is within the range of the historical vehicle control data. - Statistics:
- The statistical evaluation of the data was carried out using the program system MUKERN (BASF SE). The asymptotic U test according to MANN-WHITNEY (modified rank test according to WILCOXON) was carried out to clarify the question whether there are statistically significant differences between the untreated control group and the treated dose groups with regard to the micronucleus rate in polychromatic erythrocytes. The relative frequencies of cells containing micronuclei of each animal were used as a criterion for the rank determination for the U test. Statistical significances were identified as follows:
* p ≤ 0.05
** p ≤ 0.01
However, both biological relevance and statistical significance were considered together. - Sex:
- male
- Genotoxicity:
- negative
- Toxicity:
- yes
- Remarks:
- piloerection and hunched posture in high dose
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- According to the results of the present study, there are no statistical significances or biologically relevant differences in the frequency of erythrocytes containing micronuclei either between the vehicle control groups and the three dose groups (375 mg/kg, 750 mg/kg and 1 500 mg/kg) or between the two sacrifice intervals (24 and 48 hours). The number of normochromatic or polychromatic erythrocytes containing small micronuclei (d < D/4) or large micronuclei (d ≥ D/4) did not deviate from the vehicle control values at any of the sacrifice intervals and was within the historical vehicle control data range.
In this study, after single oral administration of the vehicle DMSO/corn oil the ratio of PCEs/NCEs in the vehicle control animals at both sacrifice intervals was within the normal range for the animal strain selected. Besides the number of cells containing micronuclei in these vehicle control animals was within the range of the historical vehicle control data both for PCEs and for NCEs.
In addition, both positive control substances, cyclophosphamide and vincristine sulfate, induced a statistically significant increase in the number of PCEs containing small and/or large micronuclei within the range of the historical positive control data or above. - Conclusions:
- Interpretation of results (migrated information): negative
According to the aouthors, under the experimental conditions chosen here, the test substance has no chromosome-damaging (clastogenic) effect nor does it lead to any impairment of chromosome distribution in the course of mitosis (aneugenic activity) in bone marrow cells of NMRI mice in vivo.
Referenceopen allclose all
Summary table – Induction of Micronuclei in bone marrow cells
Test group |
Sacrificeinterval [hrs] |
AnimalNo. |
Micronuclei in PCE |
Numberof NCEc |
|
totala[‰] |
largeb[‰] |
||||
Vehicle control DMSO/corn oil |
24 |
5 |
2.4 |
0.1 |
3 505 |
Test substance 375 mg/kg bw. |
24 |
5 |
1.3 |
0.0 |
3 490 |
Test substance 750 mg/kg bw. |
24 |
5 |
1.3 |
0.0 |
3188 |
Test substance 1 500 mg/kg bw. |
24 |
5 |
1.4 |
0.0 |
3 699 |
Positive control cyclophosphamide 20 mg/kg bw. |
24 |
5 |
13.7** |
0.1 |
4 076 |
Positive control vincristine sulfate 0.15 mg/kg bw. |
24 |
5 |
47.9** |
14.7** |
5 879 |
Vehicle control DMSO/corn oil |
48 |
5 |
1.3 |
0.0 |
4 630 |
Test substance 1 500 mg/kg bw. |
48 |
5 |
1.3 |
0.0 |
4 078 |
PCE = polychromatic erythrocytes
NCE = normochromatic erythrocytes
bw. = body weight
a= sum of small and large micronuclei
b= large micronuclei (indication for spindle poison effect)
c= number of NCEs observed when scoring 10 000 PCEs
* = p ≤ 0.05
** = p ≤ 0.01
Summary table – Induction of Micronuclei in bone marrow cells
Test group |
Sacrificeinterval [hrs] |
AnimalNo. |
Micronuclei in PCE |
Numberof NCEc |
|
totala[‰] |
largeb[‰] |
||||
Vehicle control DMSO/corn oil |
24 |
5 |
2.4 |
0.1 |
3 505 |
Test substance 375 mg/kg bw. |
24 |
5 |
1.3 |
0.0 |
3 490 |
Test substance 750 mg/kg bw. |
24 |
5 |
1.3 |
0.0 |
3188 |
Test substance 1 500 mg/kg bw. |
24 |
5 |
1.4 |
0.0 |
3 699 |
Positive control cyclophosphamide 20 mg/kg bw. |
24 |
5 |
13.7** |
0.1 |
4 076 |
Positive control vincristine sulfate 0.15 mg/kg bw. |
24 |
5 |
47.9** |
14.7** |
5 879 |
Vehicle control DMSO/corn oil |
48 |
5 |
1.3 |
0.0 |
4 630 |
Test substance 1 500 mg/kg bw. |
48 |
5 |
1.3 |
0.0 |
4 078 |
PCE = polychromatic erythrocytes
NCE = normochromatic erythrocytes
bw. = body weight
a= sum of small and large micronuclei
b= large micronuclei (indication for spindle poison effect)
c= number of NCEs observed when scoring 10 000 PCEs
* = p ≤ 0.05
** = p ≤ 0.01
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
Justification for classification or non-classification
Based on negative results in in-vitro and in-vivo studies conducted, the substance does not need to be classified for germ cell mutagenicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.